PSMA-RLT is a trade-off between sufficient tumor dose while maintaining recommended dose limits for organs at risk, including the kidneys, bone marrow, and salivary glands, which underlines the clinical importance of dosimetry during RLT [12]. The gene discussed is FOLH1; the disease is neoplasm.